Cyclin-dependent Kinase 4 and 6 Inhibitors at the Crossroads: the Combinational Therapeutic Strategies in Breast Cancer—a Narrative Review
Yiqi Yang,Sha Zhu,Ziyi Fu,Chunxiao Sun,Fan Yang,Tianyu Zeng,Yijia Hua,Shengnan Bao,Xian Gao,Xiang Huang,Wei Li,Yongmei Yin
DOI: https://doi.org/10.21037/tbcr-20-54
2021-01-01
Translational Breast Cancer Research
Abstract:The successful development of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors is of milestone significance. Since 2015, three CDK4/ 6 selective inhibitors (palbociclib, ribociclib, abemaciclib) have been developed by virtue of their outstanding performance in a series of studies, such as PALOMA, MONALEESA, and MONARCH. As CDK4/6 inhibitor monotherapy shows limited effectiveness, besides endocrine therapy (tamoxifen, AI, fulvestrant), an increasing number of laboratories and clinical researches exploring CDK4/6 inhibitor in combination with targeted therapy (HER2 targeted therapy, PI3K-mTOR/ AKT/FGFR/PARP inhibitors), chemotherapy, immunotherapy, and radiotherapy, have emerged and exhibited broad prospects in breast cancer treatment, indicating that the use of CDK4/6 inhibitors does not restrict to hormone receptor-positive and HER2-negative advanced breast cancers. This review summarizes and discusses the advances in combinational strategies of CDK4/6 inhibitors for the treatment of breast cancer to further expand its clinical efficacy, overcoming endocrine and even CDK4/6 inhibitors resistance. The combined therapies have achieved favorable clinical efficacy with tolerable adverse effects. However, more efforts are warranted to investigate the better combinations for individuals. The precise choice of target population, the extensive search of predictive biomarkers, and the deep exploration of resistance mechanisms might be the future directions, which will assist us in seeking more beneficial strategies of combined therapy for individuals to improve survival.